GP30341 capsules 200 mg + Standard therapy
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 16/100
16
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics
Conditions
Pharmacokinetics, Safety Issues, Efficacy
Trial Timeline
Mar 17, 2022 → Jul 20, 2022
NCT ID
NCT05648799About GP30341 capsules 200 mg + Standard therapy
GP30341 capsules 200 mg + Standard therapy is a pre-clinical stage product being developed by GEROPHARM for Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT05648799. Target conditions include Pharmacokinetics, Safety Issues, Efficacy.
What happened to similar drugs?
5 of 5 similar drugs in Pharmacokinetics were approved
Approved (5) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05648799 | Pre-clinical | Completed |
Competing Products
20 competing products in Pharmacokinetics